Regenxbio Inc

RGNX

Add to Watchlist

5.650USD

-0.070-1.22%

Close 05/18, 16:00（ET）Quotes delayed by 15 min

Regenxbio Inc's Score

Industry at a Glance

Industry Ranking

95 / 381

Overall Ranking

216 / 4479

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Regenxbio Inc Highlights

StrengthsRisks

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.

Overvalued

The company’s latest PE is -1.01, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 45.28M shares, decreasing 7.13% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.02K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.71.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

26.083

Target Price

+356.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Regenxbio Inc is 5.80, ranking 310 out of 381 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 6.39M, representing a year-over-year decrease of 92.82%, while its net profit experienced a year-over-year decrease of 1580.37%.

Score

Industry at a Glance

Previous score

5.80

Change

0



Financials

4.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.43

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Regenxbio Inc is 6.52, ranking 247 out of 381 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.01, which is 0.00% below the recent high of -1.01 and -357.26% above the recent low of -4.62.

Score

Industry at a Glance

Previous score

6.52

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/381

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Regenxbio Inc is 8.46, ranking 120 out of 381 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 52.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.46

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Regenxbio Inc is 6.59, ranking 190 out of 381 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.52 and the support level at 3.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-18

The current institutional shareholding score of Regenxbio Inc is 7.00, ranking 82 out of 381 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 87.72%, representing a quarter-over-quarter increase of 3.42%. The largest institutional shareholder is James Simons, holding a total of 305.29K shares, representing 0.59% of shares outstanding, with 0.05% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Redmile Group, LLC

4.37M

-6.92%

BlackRock Institutional Trust Company, N.A.

3.99M

-3.99%

Fox (Allan Mark)

2.90M

+0.27%

State Street Investment Management (US)

2.29M

+15.21%

JP Morgan Asset Management

2.53M

-2.94%

Morgan Stanley & Co. LLC

1.74M

+20.55%

Goldman Sachs & Company, Inc.

1.52M

-5.95%

AQR Capital Management, LLC

1.36M

+5.61%

Integral Health Asset Management, LLC

1.20M

+9.09%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Regenxbio Inc is 4.42, ranking 83 out of 381 in the Biotechnology & Medical Research industry. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Regenxbio Inc

RGNX

6.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment